Surface Oncology Inc SURF:NASDAQ

Last Price$1.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22

Today's Change-0.05(2.54%)
Bid (Size)$1.85 (3)
Ask (Size)$1.92 (17)
Day Low / High$1.83 - 2.04
Volume504.9 K
  • Latest Stories
  • Commentary and Analysis
Wedbush Cuts Price Target on Surface Oncology to $12 From $14, Citing 'Future Financing Assumptions,' Keeps Outperform Rating
4:43AM ET 5/12/2022 MT Newswires

Surface Oncology (SURF) has an average rating of buy and price targets ranging from $10 to $14, according to analysts polled by Capital IQ. (MT Newswires...

Surface Oncology Starts Two Mid-Stage Trials of Experimental Cancer Drug
8:13AM ET 4/14/2022 MT Newswires

Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a...

Surface Oncology Secures $30 Million Milestone Payment After First Patient Dosed in Study; Shares Rise
8:00AM ET 3/31/2022 MT Newswires

Surface Oncology (SURF) said Thursday that it has received a $30 million milestone payment as GlaxoSmithKline (GSK) has dosed the first patient in a phase...

Surface Oncology Names Denice Torres as Chair of Board of Directors
7:43AM ET 12/15/2021 MT Newswires

Surface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...

Surface Oncology Gets US FDA Clearance for Human Clinical Trial of Potential Anti-Tumor Therapy
8:39AM ET 12/01/2021 MT Newswires

Surface Oncology (SURF) said Wednesday the US Food and Drug Administration has cleared the company's investigational new drug application for its...

-- Earnings Flash (SURF) SURFACE ONCOLOGY Posts Q3 Revenue $392,000
7:18AM ET 11/04/2021 MT Newswires


Surface Oncology to Study Potential Antibody's Use For Treatment-Naive Hepatocellular Carcinoma
8:55AM ET 10/04/2021 MT Newswires

Surface Oncology (SURF) on Monday announced plans to start a randomized Phase 2 clinical study evaluating its SRF388 potential antibody against IL-27 in...

Top Premarket Gainers
8:11AM ET 9/17/2021 MT Newswires

Corvus Pharmaceuticals (CRVS) shares soared 52% following a small loss on Thursday. Innate Pharma (IPHA) shares rallied 29% on positive phase 2 trial data...

--Wedbush Adjusts Price Target for Surface Oncology to $14 From $18, Maintains Outperform Rating
4:26PM ET 8/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (SURF) SURFACE ONCOLOGY Posts Q2 Revenue $515,000
7:18AM ET 8/05/2021 MT Newswires